StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Alkem Laboratories (ALKEM)

Pharma · NSE · end-of-day 2026-10-19

₹5,004.00

Day change

-0.91%

1-year

-8.7%

From 52-week high

-15.0%

Weinstein stage

Stage 4

Minervini template

1/8

Alkem Laboratories closed at ₹5,004.00 on 2026-10-19, down 9% over the past year, 15% below its 52-week high. It meets 1 of 8 conditions of Minervini's trend template; Weinstein's stage analysis reads stage 4 - declining; on earnings, it passes 0 of 5 SEPA checks. Over the year its annualised volatility was about 22%, with a largest fall of 15% from a peak.

About Alkem Laboratories

Alkem Laboratories Limited develops, manufactures, and markets branded generics, specialty pharmaceuticals, and Active Pharmaceutical Ingredients (APIs). The company has a strong presence in domestic therapeutic segments while expanding its footprint in regulated international markets. Investments in research, manufacturing quality, and product development strengthen long-term competitiveness. A diversified therapeutic portfolio reduces dependence on individual products. Growing healthcare demand and chronic disease treatment continue to support expansion.

Price, RSI and MACD

6M1Y2Y3Y

Price · -11.3% over the period

RSI (14) · 36.3

MACD (12, 26, 9) · histogram -21.32

Price · -8.3% over the period

RSI (14) · 36.3

MACD (12, 26, 9) · histogram -21.32

Price · -19.2% over the period

RSI (14) · 36.3

MACD (12, 26, 9) · histogram -21.32

Price · +41.7% over the period

RSI (14) · 36.3

MACD (12, 26, 9) · histogram -21.32

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	ROE previous year	ROCE	Debt / equity	Free cash flow	EV / EBITDA	Beta
₹59,823 cr	₹15,081 cr	₹2,204 cr	27.7	180.44	4.33	17.8%	19.4%	20.6%	0.12	₹1,476 cr	18.1	0.66

Quarterly results

Quarter	Sales ₹ cr	Net profit ₹ cr	EPS	EPS YoY	Sales YoY	Net margin
Jun 2026	3,740	521	43.49	-21.7%	+10.9%	13.9%
Mar 2026	3,603	251	19.77	-22.7%	+14.6%	7.0%
Dec 2025	3,737	653	53.19	+1.6%	+10.7%	17.5%
Sep 2025	4,001	779	63.99	+11.1%	+17.2%	19.5%
Jun 2025	3,371	668	55.56	+21.8%	+11.2%	19.8%
Mar 2025	3,144	322	25.57	+4.2%	+7.1%	10.2%
Dec 2024	3,374	641	52.34	+5.2%	+1.5%	19.0%
Sep 2024	3,415	702	57.60	+11.0%	-0.7%	20.6%

Consolidated · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 0 of 5 pass

Check	Result
Latest quarter EPS up 25%+ on a year ago	✗ Fail
EPS growth accelerating over 3 quarters	✗ Fail
Sales up 25%+, or sales growth accelerating	✗ Fail
Annual EPS up 25%+ in each of the last 2 years	✗ Fail
Net margin above the same quarter last year	✗ Fail

Investor methods

Method	Checks	Score	Verdict
Minervini	✗ Close above the 150- and 200-day averages ✗ 150-day above 200-day ✗ 200-day rising for a month ✗ 50-day above the 150- and 200-day ✗ Close above the 50-day ✗ At least 25% above the 52-week low · low 5,004.00 ✓ Within 25% of the 52-week high · high 5,890.00 ✗ RS percentile 70 or more · RS 38 Trend template - the gate, measured: a modest 21-day edge.	1/8	1 of 8
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 4 - declining
CAN SLIM	✗ C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 5,890.00 ✗ S more volume on up days than down days (50 sessions) · 0.84x ✗ L RS percentile 80 or more · RS 38 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist.	1/6	Weak
Darvas	✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box.	10/100	No box
Turtle	✗ Close above the prior 55-session high · 5,882.50 ✗ Close above the prior 20-session high · 5,466.50 ✓ Close below the prior 20-session low · 5,042.00 Donchian channel breakout - the Turtle traders' entry.		Breakdown
Greenblatt	— Earnings yield (EBITDA / EV) · 5.5% — Return on capital (ROCE) · 20.6% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately.	64/100	Average
Graham	✗ Price at or below the Graham number · Graham number 2,166.07 ✗ P/E 15 or less · P/E 27.7 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 4.33 ✓ Current ratio 2 or more · 2.55 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests.	43/100	Expensive
Piotroski	✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✗ Cash flow above net profit (earnings quality) ✗ Long-term debt / assets falling ✗ Current ratio rising · 2.55 ✓ No new shares issued ✗ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026.	3/9	Weak

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
ALKEM this stock	-8.5	-11.5	-11.3	-10.3	+38.4	+30.2	27.7	4.33	17.8	20.6	—	0.12	18.1	59,823	15,081	2,204	180.4	0.66
BLISSGVS	-8.0	+29.9	+147.2	+312.3	+606.5	+476.9	48.7	5.57	11.5	16.8	—	0.00	29.3	6,650	1,005	142	12.9	1.10
VENUSREM	+0.7	-5.9	+55.8	+252.6	+518.8	+242.4	18.3	3.21	16.8	21.9	—	0.00	13.7	2,130	811	116	86.9	0.88
INDSWFTLAB	-5.7	+50.4	+153.3	+247.2	+287.1	+472.2	51.6	2.21	3.2	3.9	—	0.01	33.4	3,056	665	57	6.8	0.78
MOREPENLAB	+0.5	+108.6	+194.2	+152.6	+242.7	+132.7	47.5	5.34	7.9	10.1	—	0.16	40.2	6,657	1,951	140	2.6	1.46
SHILPAMED	-14.2	+40.1	+113.1	+146.1	+421.3	+189.7	57.3	6.61	9.8	11.4	—	0.25	—	17,130	1,682	297	15.3	0.87
RUBICON	-15.1	-1.7	+60.3	+140.3	—	—	83.8	19.08	22.4	—	—	0.20	61.3	24,587	1,936	288	17.7	0.34
LAURUSLABS	+5.9	+32.7	+83.2	+129.9	+421.9	+235.3	88.9	21.09	18.2	17.9	—	0.45	62.0	1.12L	8,839	1,252	23.3	0.74
ZIMLAB	+2.0	+14.2	+73.3	+101.9	+17.5	—	168.5	2.50	2.1	5.5	—	0.42	21.1	740	397	4	0.8	0.75
ACUTAAS	-5.4	-11.0	+35.0	+97.5	—	—	69.0	16.11	24.0	31.7	—	0.02	49.9	26,636	1,462	387	47.2	0.77
IOLCP	-9.8	+17.8	+108.9	+87.8	+99.0	+56.2	32.0	2.99	7.9	10.7	—	0.07	20.7	5,376	2,524	168	5.7	1.13

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Glenmark Pharma Biocon Abbott India Gland Pharma IPCA Laboratories Anthem Biosciences Limited GSK Pharma Ajanta Pharma

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact